AstraZeneca jointly developed the drug with Japan's Daiichi Sankyo. “Despite many efforts to surpass docetaxel with novel approaches in previously treated advanced or metastatic non-small cell ...

Furthermore, docetaxel (the drug of choice for the first-line treatment of castration-resistant PC) cannot cross the blood–brain barrier and control metastatic foci. However, this problem may be ...

An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...

Sequential intravesical gemcitabine and docetaxel is associated with better oncologic outcomes compared with additional BCG in patients with BCG-unresponsive NMIBC and warrants a trial.

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel ...

While lower relative dose intensity of docetaxel was associated with higher rates of G-CSF use and more adverse events, ...

New Data for NUBEQA® Build on Safety and Efficacy Results Across Subgroups of Patients with Metastatic Hormone-Sensitive ...

A recent study suggests that sequential intravesical treatment with gemcitabine and docetaxel is more effective than additional bacillus Calmette-Guérin (BCG) therapy for patients with BCG ...